Drug Trial Radar · NCT04873362
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,188
Actual
Start
May 4, 2021
Primary completion
Mar 31, 2027
Study completion Oct 2, 2034
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.
Conditions
- Breast Cancer
Interventions
AtezolizumabDrug
Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.
Trastuzumab EmtansineDrug
Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.
PlaceboDrug
Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.
TrastuzumabDrug
Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-free Survival (IDFS) in the Full Analysis Set (FAS)Time frame: From baseline until the first occurrence of iDFS event or death, through primary analysis data cut off (approximately 7 years)
Locations
238 sites in 32 countries. Site status is shown where the registry gives one.
Alabama Oncology
Birmingham, Alabama
Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center
Buena, California
UCLA Medical Center
Santa Monica, California
Innovation Clinical Research Institute
Whittier, California
Florida Cancer Specialists
West Palm Beach, Florida
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
Carrollton, Georgia
University of Iowa
Iowa City, Iowa
New England Cancer Specialists
Westbrook, Maine
The Valley Hospital
Paramus, New Jersey
Levine Cancer Institute
Charlotte, North Carolina
Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit
Philadelphia, Pennsylvania
The West Clinic
Germantown, Tennessee
Thompson Cancer Survival Center
Knoxville, Tennessee
Mays Cancer Center at UT Health San Antonio MD Anderson Cancer
San Antonio, Texas
Hematology Oncology Associates of Fredericksburg, Inc.
Fredericksburg, Virginia
Virginia Oncology Associates - New Port News
Newport News, Virginia
Virginia Oncology Associates
Norfolk, Virginia
Virginia Cancer Institute
Richmond, Virginia
Virginia Oncology Associates - Virginia Beach
Virginia Beach, Virginia
Providence Regional Cancer Partnership
Everett, Washington
Kadlec Clinic Hematology and Oncology
Kennewick, Washington
Northwest Medical Specialties
Tacoma, Washington
Macarthur Cancer Therapy Centre
Campbelltown, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Tiroler Landeskrankenanstalten Ges.M.B.H.
Innsbruck, Austria
Ordensklinikum Linz Barmherzige Schwestern
Linz, Austria
Lkh Salzburg - Univ. Klinikum Salzburg
Salzburg, Austria
Cliniques Universitaires St-Luc
Brussels, Belgium
Jessa Zkh (Campus Virga Jesse)
Hasselt, Belgium
Clinique St. Elizabeth
Namur, Belgium
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Hospital Sao Rafael - HSR
Salvador, Estado de Bahia, Brazil
Hospital Araujo Jorge
Goiânia, Goiás, Brazil
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Base de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
São Paulo, São Paulo, Brazil
Showing 40 of 238 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.